Review
Open access
Aug 2026
Landscape of Actionable Genetic Alterations in Advanced Urothelial Carcinoma: High Prevalence but Limited Clinical Use.
BACKGROUND AND OBJECTIVE The Food and Drug Administration and the European Medicine Agency approved erdafitinib for patients with FGFR3-altered metastatic urothelial carcinoma (mUC), highlighting the central role of tumor molecular profiling for patients with mUC. Although different studies described the molecular land...
M. G. Carta, L. Tögel, M. Angeloni et al.
· European Urology Oncology · 0 citations